Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HRA Pharma UK

- PMLiVE

GSK to acquire Bellus Health for approximately $2bn

The deal includes the biotech’s late-stage candidate for refractory chronic cough

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate

There are currently no licensed vaccines offering simultaneous protection against all five serogroups

- PMLiVE

Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine

RSV infections in older adults account for around 6,000 to 10,000 deaths in the US each year

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

GSK’s Jemperli shows promise in phase 3 endometrial cancer trial

An interim analysis noted the trial met its primary endpoint of progression-free survival

- PMLiVE

GSK’s new global survey exposes lupus treatment gaps

The findings show opportunities to address organ damage risk for early stage lupus patients

Bayer symbol

Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer

The treatment will be made available immediately through an early access deal with NHS England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links